Stock Symbol EW Financial Information and Analysis

The stock symbol EW is a popular choice among investors, and for good reason. It's a unique identifier that provides a wealth of financial information and analysis.

EW is a widely traded ETF that tracks the MSCI EAFE Index, which covers developed markets outside of the US and Canada. This index includes over 900 stocks from 21 countries.

Investors who follow the EW stock symbol can gain exposure to a diverse range of international markets. This can be a great way to diversify a portfolio and potentially reduce risk.

Edwards Lifesciences, the company behind the stock symbol EW, has seen significant growth in its revenue over the past year, with a 11.56% increase in 2023 to $6.00 billion.

Its earnings have also been on the rise, with a $1.40 billion earnings in 2023, although this represents a decrease of -7.85% compared to the previous year.

The company's financial performance is expected to continue growing, with estimates suggesting a revenue of $5,824 million in 2025.

Edwards Lifesciences' dividend yield has been 0.00% in 2025, with no dividend payments expected.

The company's earnings per share (EPS) are expected to reach $2.44 in 2025, with a price-to-earnings (P/E) ratio of 29.66.

Here's a breakdown of the company's financial estimates for 2025-2028:

The company's research and development expenses are expected to reach $1,460 million in 2028.

Edwards Lifesciences' net debt has been decreasing over the past few years, with a net debt of -$3,626 million in 2025.

The company's free cash flow is expected to reach $2,326 million in 2028.

The number of analysts estimating Edwards Lifesciences' earnings has been decreasing over the past quarter, with 23 analysts estimating earnings in the current quarter.

The average earnings estimate for the current quarter is $0.588 USD.

The number of analysts estimating Edwards Lifesciences' revenue has also been decreasing over the past quarter, with 19 analysts estimating revenue in the current quarter.

The average revenue estimate for the current quarter is $1,414 USD.

The company's diluted EPS (TTM) has been $2.086, with a revenue growth of 8.9% and earnings growth of 716% in the past year.

The company's profit margin has been 65.9%.

Edwards Lifesciences, with stock symbol EW, has shown significant growth in its revenue, with a 11.56% increase in 2023 to $6.00 billion.

The company's earnings, however, saw a decline of -7.85% to $1.40 billion in 2023. This mixed performance highlights the need for a closer look at the company's stock performance.

In terms of stock performance, EW has a market cap of $34,414,699,223.04 and is listed on the NYSE. The stock's price range has been quite volatile, with a year range of $46.712 to $77.316.

Here's a quick summary of EW's stock performance:

The stock's price history shows some fluctuations, with a 52-week high of $96.12 and a 52-week low of $58.93. The current share price is $72.45, a -1.98% change from the previous month.

Edwards Lifesciences Corporation is a company that provides products and technologies for structural heart disease and critical care monitoring globally. The company is listed on the NYSE under the stock symbol EW.

Edwards Lifesciences has outlined its strategy for long-term sustainable growth, which includes a focus on innovations in structural heart therapies. The company has a technology pipeline that is being updated and expanded.

The company's stock performance is publicly available and can be checked for past financial performance and market value. Edwards Lifesciences Corp's past financial performance includes revenue and net income data.

Here is a summary of the company's fundamental analysis:

Edwards Lifesciences Corp has a Price-To-Earnings ratio of 27.3x, which is below the Medical Equipment industry average of 36x.

Edwards Lifesciences Corp is a company that provides products and technologies for structural heart disease and critical care monitoring in various countries, including the United States, Europe, Japan, and internationally.

The company's stock performance is publicly available, showing a revenue and net income history, as well as its current market value.

Edwards Lifesciences Corp has a Snowflake Score, which is a measure of its fundamental analysis, including valuation, future growth, past performance, financial health, and dividends.

Here's a breakdown of the company's Snowflake Score:

The company's Price-To-Earnings ratio is 27.3x, which is below the Medical Equipment industry average of 36x.

The management team at Edwards Lifesciences is comprised of experienced professionals who oversee the company's operations and strategy.

Nicholas J. Valeriani serves as the Chairman of the board, bringing his expertise to the table.

Bernard J. Zovighian is the President, Chief Executive Officer, and Director, responsible for leading the company's overall direction.

The company has a total of 23 members on its management team, including various vice presidents and directors.

Here is a list of the company's management team, including their job titles and areas of responsibility:

Edwards Lifesciences has a focused strategy for long-term sustainable growth. The company outlined its vision for growth at its annual investor conference.

At the conference, Edwards Lifesciences provided an update on its technology pipeline, which is expected to drive future growth. The company's technology pipeline is a key area of focus for its long-term growth strategy.

Edwards Lifesciences provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. The company's products and technologies are used in various medical settings.

The company's growth strategy is centered around innovations in structural heart therapies. Edwards Lifesciences detailed its strategy for sustained long-term growth and innovations in structural heart therapies at its annual investor conference.

Here's a breakdown of Edwards Lifesciences' strategy for growth:

The company's Price-To-Earnings ratio (27.3x) is below the Medical Equipment industry average (36x). This suggests that Edwards Lifesciences may be undervalued compared to its peers.